Skip to NavigationSkip to content

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Atopic Dermatitis in 17 Major Markets - ref #BS000021

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Atopic Dermatitis in 17 Major Markets 

Atopic Dermatitis, also known as eczema, is a common disorder of the epidermis of the skin causing dryness, itchiness, red rashes, inflammation, sores and blisters. It occurs mostly in early childhood and can develop from exposure to allergens and irritants, such as dust mites, pollen, peanuts and so forth. The prognosis for most patients is improvement in symptoms, and by adulthood it may disappear altogether.

 

This report provides the current prevalent population for Atopic Dermatitis across 17 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Turkey, Mexico, Canada, Australia, South Africa, Poland, Russia and China) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of severity, location and IgE levels of Atopic Dermatitis, to name a few. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.  

 

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Atopic Dermatitis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Atopic Dermatitis include:

·         Asthma

·         Rhinitis

·         Allergies (Food or Inhalant-related)

·         Rashes

·         Eczemic lesions

 

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reasons to buy

  • Able to quantify patient populations in global Atopic Dermatitis’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Atopic Dermatitis and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Atopic Dermatitis’s prevalent population.
  • Identify sub-populations within Atopic Dermatitis which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Atopic Dermatitis patients.

Publisher: Black Swan
Publication date: November 2015
 

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Atopic Dermatitis in 17 Major Markets

Atopic Dermatitis, also known as eczema, is a common disorder of the epidermis of the skin causing dryness, itchiness, red rashes, inflammation, sores and blisters. It occurs mostly in early childhood and can develop from exposure to allergens and irritants, such as dust mites, pollen, peanuts and so forth. The prognosis for most patients is improvement in symptoms, and by adulthood it may disappear altogether.

 

This report provides the current prevalent population for Atopic Dermatitis across 17 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Turkey, Mexico, Canada, Australia, South Africa, Poland, Russia and China) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of severity, location and IgE levels of Atopic Dermatitis, to name a few. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.  

 

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Atopic Dermatitis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Atopic Dermatitis include:

·         Asthma

·         Rhinitis

·         Allergies (Food or Inhalant-related)

·         Rashes

·         Eczemic lesions

 

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

·         Able to quantify patient populations in global Atopic Dermatitis’s market to target the development of future products, pricing strategies and launch plans.

·         Gain further insight into the prevalence of the subdivided types of Atopic Dermatitis and identify patient segments with high potential.

·         Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

·         Provide a level of understanding on the impact from specific co-morbid conditions on Atopic Dermatitis’s prevalent population.

·         Identify sub-populations within Atopic Dermatitis which require treatment.

·         Gain an understanding of the specific markets that have the largest number of Atopic Dermatitis patients.

Publisher: Black Swan
Publication date: November 2015

 

 

 

 

Price: £ 3,950.00

You need to agree to the Terms and Conditions before placing your order

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches